Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary
It's a phase 2, single arm study of gemcitabine an docetaxel combination in patients with carcinoma of unknown primary.
Carcinoma of Unknown Primary
DRUG: gemcitabine/docetaxel combination
Overall survival, one year after later patients enrolled
It's a phase 2, single arm study of gemcitabine an docetaxel combination in patients with carcinoma of unknown primary.